Literature DB >> 33603959

Novel Galectin-3 Inhibitors for Treating Fibrosis.

Ram W Sabnis1.   

Abstract

Entities:  

Year:  2021        PMID： 33603959      PMCID： PMC7883374          DOI： 10.1021/acsmedchemlett.0c00671

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.345


× No keyword cloud information.
  4 in total

Review 1.  Research progress on the role of gal-3 in cardio/cerebrovascular diseases.

Authors:  Zhan-Qi Cao; Xin Yu; Ping Leng
Journal:  Biomed Pharmacother       Date:  2020-12-04       Impact factor: 6.529

Review 2.  Galectins as potential pharmacological targets in renal injuries of diverse etiology.

Authors:  Ming Gu; Xianglin Mei; Yanan Zhao
Journal:  Eur J Pharmacol       Date:  2020-05-22       Impact factor: 4.432

3.  Galectins as Regulators of Corneal Inflammation.

Authors:  Pablo Argüeso
Journal:  Curr Opin Physiol       Date:  2020-09-07

Review 4.  Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy.

Authors:  Peter M George; Athol U Wells; R Gisli Jenkins
Journal:  Lancet Respir Med       Date:  2020-05-15       Impact factor: 30.700
  4 in total
  1 in total

1.  Multicomponent reaction derived small di- and tri-carbohydrate-based glycomimetics as tools for probing lectin specificity.

Authors:  Andreja Jakas; Ramya Ayyalasomayajula; Mare Cudic; Ivanka Jerić
Journal:  Glycoconj J       Date:  2022-08-24       Impact factor: 3.009
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.